InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China



BEIJING, Feb. 08, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to conduct clinical trials of ICP-538, a VAV1-directed molecular glue degrader (MGD). This is the first VAV1 degrader approved to enter clinical trials in China and the second globally. Read More



Source link

  • Related Posts

    Thai Stocks Tied to Incumbent PM Anutin Jump on Surprise Win

    The stock jumped as much as 22% on Monday, the most since Sept. 2024, after preliminary results showed Bhumjaithai Party secured 191 seats in the 500-member parliament. It is among…

    Why is Singapore no longer “cool”?

    To be clear, I am not blaming Singapore on this one.  But it is striking to me how much Americans do not talk about Singapore any more.  They are much,…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Japan’s Takaichi vows to deliver on tax cuts after LDP’s ‘historic’ win | Politics News

    Japan’s Takaichi vows to deliver on tax cuts after LDP’s ‘historic’ win | Politics News

    Thai Stocks Tied to Incumbent PM Anutin Jump on Surprise Win

    The 4 Best Easy Spring Outfits With Jeans

    The 4 Best Easy Spring Outfits With Jeans

    Bad Bunny hands his Grammy to young boy during Super Bowl halftime show

    Bad Bunny hands his Grammy to young boy during Super Bowl halftime show

    Super Bowl 2026 commercials: Athletes include Serena, more

    Super Bowl 2026 commercials: Athletes include Serena, more

    Why is Singapore no longer “cool”?

    Why is Singapore no longer “cool”?